DCF Advisers LLC Increases Stock Position in Evotec AG (NASDAQ:EVO)

Key Points

• DCF Advisers LLC increased its holdings in Evotec AG by 227.0% in the first quarter, acquiring an additional 521,708 shares to reach a total of 751,579 shares.
• Recent Hedge fund movements include Bank of America raising its position in Evotec by 262.5%, reflecting growing institutional interest in the stock.
• Wall Street analysts maintain a positive outlook with Royal Bank Of Canada reiterating an "outperform" rating and Deutsche Bank upgrading its rating from "sell" to "hold".

DCF Advisers LLC lifted its stake in Evotec AG (NASDAQ:EVO - Free Report) by 227.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 751,579 shares of the company's stock after acquiring an additional 521,708 shares during the period. Evotec makes up about 1.2% of DCF Advisers LLC's holdings, making the stock its 28th largest holding. DCF Advisers LLC owned 0.21% of Evotec worth $2,510,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of EVO. BNP Paribas Financial Markets bought a new stake in shares of Evotec in the fourth quarter valued at about $27,000. CSS LLC IL purchased a new stake in shares of Evotec in the fourth quarter valued at $50,000. Bank of America Corp DE boosted its holdings in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares during the period. Finally, Lighthouse Investment Partners LLC bought a new position in shares of Evotec in the 4th quarter worth about $166,000. 5.81% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

EVO has been the subject of several research reports. Royal Bank Of Canada reissued an "outperform" rating on shares of Evotec in a research note on Thursday, May 15th. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th.

Evotec Stock Performance

Shares of EVO stock traded up $0.11 during trading hours on Thursday, reaching $3.86. 19,122 shares of the company traded hands, compared to its average volume of 99,011. The company has a quick ratio of 1.93, a current ratio of 2.03 and a debt-to-equity ratio of 0.46. Evotec AG has a 12-month low of $2.84 and a 12-month high of $5.64. The firm has a 50-day moving average price of $4.08 and a 200 day moving average price of $3.99.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.